Pall Corp. Signs Agreement with ATMI
News Dec 27, 2013
Pall Corporation has announced that it has entered into a definitive agreement with ATMI, Inc. to acquire the ATMI LifeSciences business for $185 million.
ATMI LifeSciences is a technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries.
The transaction, which is expected to close in Pall’s fiscal third quarter, is subject to certain closing conditions, regulatory approvals and labor-related notifications.
“This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,” said Larry Kingsley, Pall Chairman and CEO.
Doug Neugold, ATMI’s Chief Executive Officer, said, “We are very happy to have Pall as the new owner of this business, and believe the fit and their capabilities will accelerate its growth and provide great support to our customers.”
For the balance of fiscal 2014, Pall expects the acquisition to add $20 - $30 million in revenue, be $0.05 - $0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis.
Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30 - $3.50.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018